3Kaufman SE, Donnell RW, Hickey WS. Rationale and evidence for extended infusion of piperacillin-tazobactam[J]. Am J Health Syst Pharm,2011,68(16):1521.
4Yusuf E,Spapen H, Pierard D. Prolonged vs intermittent infusion of piperacillin/tazobactam in crtically ill patients:A narrative and systematic review[J]. J Crrit Care,2014,29(6):1089-1095.
5Falagas ME, Tansarli GS, Ikawa K, et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis[J]. Clin Infect Dis,2013,56(2):272-282.
6Eiki K, Junko K, Yasuyuki N, et al. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions[J]. Antimicrob Agents Chemother,2009,53(7): 2799-2803.
7Suyamah H, Ikawa K, Morikawa N, et al. Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration[J]. Jpn J Antibiot,2008,61(5): 303-313.
8De Waele J, Carlier M, Hoste E, et al. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis[J].Minerva Anestesiol,2014,21(6):389-395.
9Langan KM, Jacob J, Li J,et al. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study[J].Crit Care Resusc,2014,16(3):190-196.
10Felton TW, Hope WW, Lomaestro BM, et al. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections[J]. Antimicrob Agents Chemother,2012,56(8):4087-4094.
